High prevalence of smoldering myeloma observed in nationwide screening study

In an article in CancerTherapyAdvisor.com the iStopMM study and it‘s results are covered. Results from the study were presented at the 2021 American Society of Hematology (ASH) Annual Meeting in december. Sigrun Thorsteinsdottir, MD, PhD of The University of Iceland from the iStopMM research team says: “These results underline the necessity for improved risk stratification in smoldering myeloma. The high prevalence of smoldering myeloma has implications for future treatment policies because … treatment initiation at the smoldering stage is likely to be included in guidelines soon.”